Albireo Reports Third Quarter 2017 Financial Results
Albireo Pharma, Inc. (ALBO)
Last albireo pharma, inc. earnings: 3/2 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.albireopharma.com/investor-relations
Company Research
Source: GlobeNewswire
— Executing towards planned A4250 Phase 3 PFIC trial —— Decision on potential approval of elobixibat in Japan expected in the first half of 2018 — BOSTON, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today reported its financial results for the third quarter and nine months ended September 30, 2017 and provided a business update. “In the third quarter, we took key steps toward our goal of bringing A4250 as a non-surgical treatment option to children suffering from progressive familial intrahepatic cholestasis (PFIC), a devastating and rare genetic liver disease for which there is no approved drug treatment,” said Ron Cooper, President and Chief Executive Officer of Albireo. “In particular, as we are developing A4250 to treat a pediatric population, we were delighted that the European Medicines Agency’s Paediatric Committee, which is responsible for activities on
Show less
Read more
Impact Snapshot
Event Time:
ALBO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALBO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALBO alerts
High impacting Albireo Pharma, Inc. news events
Weekly update
A roundup of the hottest topics